The insulin infusion pumps market is anticipated to prosper as a result of factors including rising sedentary lifestyles, an aging population base that is more susceptible to developing diabetes, and a growing emphasis on enhancing the safety and usability of insulin infusion pumps. These factors are also anticipated to contribute to the insulin infusion market’s appreciable revenue growth throughout the forecast period (2022–2027).
New York, USA, Oct. 26, 2022 (GLOBE NEWSWIRE) — The Global Insulin Infusion Pumps Market to Surge at a Significant CAGR of 8.69% by 2027, Assesses DelveInsight
The insulin infusion pumps market is anticipated to prosper as a result of factors including rising sedentary lifestyles, an aging population base that is more susceptible to developing diabetes, and a growing emphasis on enhancing the safety and usability of insulin infusion pumps. These factors are also anticipated to contribute to the insulin infusion market’s appreciable revenue growth throughout the forecast period (2022–2027).
DelveInsight’s Insulin Infusion Pumps Market Insights report provides the current and forecast market, forthcoming device innovation, individual leading companies’ market shares, challenges, insulin infusion pumps market drivers, barriers, and trends, and key insulin infusion pumps companies in the market.
Key Takeaways from the Insulin Infusion Pumps Market Report
As per DelveInsight estimates, North America is anticipated to dominate the global insulin infusion pumps market during the forecast period.
Notable insulin infusion pumps companies such as F. Hoffmann-La Roche Ltd, Medtronic, Medtrum Technologies Inc., A. Menarini Diagnostic’s s.r.l., IA Collaborative Holdings, LLC, Apex Medical, Insulet Corporation, Ascensia Diabetes Care Holdings AG, Ypsomed AG, Tandem Diabetes Care, Inc., ICU Medical, Inc., SOOIL Developments Co., Ltd., MicroPort Scientific Corporation, Microtec Medical, and several others are currently operating in the insulin infusion pumps market.
In September 2020, Medtronic received the U.S. Food and Drug Administration (FDA) clearance for its MiniMed 770G system, a new insulin pump system providing smartphone connectivity and an expanded age indication to ages 2 and above.
In October 2019, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) had expanded the label for Fiasp® (insulin aspart injection) to be included in insulin infusion pumps to improve glycaemic control in adults with type 1 or type 2 diabetes.
In February 2019, Tandem Diabetes Care, received U.S. Food and Drug Administration (FDA) approval for its Slim X2 insulin pump that is used for delivering insulin under the skin for children and adults with diabetes.
To read more about the latest highlights related to the insulin infusion pumps market, get a snapshot of the key highlights entailed in the Global Insulin Infusion Pumps Market Report
Insulin Infusion Pumps Overview
An insulin infusion pump is a small, portable medical device that is worn externally, either in the patient’s pocket or on a designated belt and is used to administer insulin for the management of diabetes mellitus.
An insulin pen or a conventional regular injection device is replaced by insulin infusion pumps. The insulin infusion pumps are less painful, more reliable, and less prone to large changes in blood glucose levels than injections. Turning to the use of infusion pumps makes it more convenient for patients because it does not require meal timing to be prepared. Subcutaneous insulin injection is another name for insulin therapy.
Insulin Infusion Pumps Market Insights
North America is anticipated to generate the most revenue in the insulin infusion pumps market globally. This can be attributed to a number of factors in the region, including the presence of a sizable patient pool associated with diabetes, which can also be attributed to an increase in sedentary lifestyle, high consumer awareness regarding new market launches, the local presence of key insulin infusion pumps market players and others.
Moreover, the presence of a sizable user base for insulin infusion pumps combined with manufacturers’ increased focus on releasing new products into the market is anticipated to support the growth of the insulin infusion pumps market in the United States during the forecast period.
To know more about why North America is leading the market growth in the insulin infusion pumps market, get a snapshot of the Insulin Infusion Pumps Market Trends
Insulin Infusion Pumps Market Dynamics
The rising incidence of diabetes, growing public awareness of the disease, and unhealthy lifestyle choices are some notable factors responsible for the insulin infusion pumps market growth. Additionally, a significant driver of the development of insulin infusion pumps is the aging population, which is particularly susceptible to developing diabetes. Moreover, another significant driver of the insulin infusion pumps market expansion is the numerous benefits connected with these devices.
However, the availability of substitute products and the high price of insulin infusion pumps, might serve as restraints to the insulin infusion pumps market growth.
Additionally, due to the implementation of lockdown as necessary precautions to stop the spread of COVID-19 infection, the insulin infusion pumps market experienced a brief period of market growth restraint during the early stages of the pandemic. As a result, the production and supply of insulin infusion pumps was stopped, which ultimately resulted in a global shortage of the device in hospitals and retail pharmacies. Additionally, because diabetes patients had a very high risk of developing COVID, most of them were advised to stay inside as much as possible, contributing to the decline of insulin infusion pumps.
Later on, however, due to some lockdown easing and for the safety of diabetic patients who cannot survive without insulin, the demand for the pumps increased, and the insulin infusion pumps, as well as other necessary medications, started actively being delivered at homes through e-commerce websites. The insulin infusion pumps market has therefore experienced growth during the forecast period of 2022–2027 due to the resumption of activities across industries, including the healthcare sector.
Get a sneak peek at the insulin infusion pumps market dynamics @Insulin Infusion Pumps Market Dynamics Analysis
Report Metrics
Details
Coverage
Global
Study Period
2019–2027
Base Year
2021
Market CAGR
8.69%
Projected Insulin Infusion Pumps Market Size by 2027
USD 10.68 Billion
Key Insulin Infusion Pumps Companies
F. Hoffmann-La Roche Ltd, Medtronic, Medtrum Technologies Inc., A. Menarini Diagnostic’s s.r.l., IA Collaborative Holdings, LLC, Apex Medical, Insulet Corporation, Ascensia Diabetes Care Holdings AG, Ypsomed AG, Tandem Diabetes Care, Inc., ICU Medical, Inc., SOOIL Developments Co., Ltd., MicroPort Scientific Corporation, Microtec Medical, and others
Insulin Infusion Pumps Market Segmentation
Market Segmentation By Product Type: Patch Pump, Tethered Pump and Others
Market Segmentation By Component Type: Insulin Pump, Infusion Sets, Reservoir
Market Segmentation By Distribution Channel: Hospitals and Retail Pharmacy, E-Commerce Sites, and Others
Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View
Which MedTech key players in the insulin infusion pumps market are set to emerge as the trendsetter explore @Insulin Infusion Pumps Companies
Table of Contents
1
Report Introduction
2
Executive summary
3
Regulatory and Patent Analysis
4
Key Factors Analysis
5
Porter’s Five Forces Analysis
6
COVID-19 Impact Analysis on Insulin Infusion Pumps Market
7
Insulin Infusion Pumps Market Layout
8
Global Company Share Analysis – Key 3-5 Companies
9
Insulin Infusion Pumps Market Company and Product Profiles
10
Project Approach
11
About DelveInsight
Interested in knowing the insulin infusion pumps market by 2027? Click to get a snapshot of the Insulin Infusion Pumps Market Research
Related Reports
Type 1 Diabetes Market
Type 1 Diabetes Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key type 1 diabetes companies including Histogen, Novo Nordisk, Prevention Bio, among others.
Diabetes Market
Diabetes Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key diabetes companies, including TikoMed, Avotres, REMD Biotherapeutics, Novo Nordisk, among others.
Type 2 Diabetes Market
Type 2 Diabetes Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key type 2 diabetes companies, including Sanofi, Eli Lilly and Company, AstraZeneca, Novartis, among others.
Smart Insulin Pens Market
Smart Insulin Pens Market Insight, Competitive Landscape, and Market Forecast – 2027 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key smart insulin pens companies, including Emperra GmbH E-Health Technologies, Jiangsu Deflu Medical Device Co. Ltd., among others.
Insulin Pens Market
Insulin Pens Market Insight, Competitive Landscape, and Market Forecast – 2027 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key insulin pens companies, including Novo Nordisk A/S, Owen Mumford Ltd, Sanofi Diabetes, Merck Sharp & Dohme Corp., Insulet Corporation, among others.
Insulin Delivery Devices Market
Insulin Delivery Devices Market Insight, Competitive Landscape, and Market Forecast – 2027 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key insulin delivery devices companies, including Becton, Dickinson and Company, Medtronic, Novo Nordisk A/S, Ypsomed Holding AG, among others.
Other Trending Reports
Goitre Market | Thymus Cancer Market | US Healthcare Outlook Report | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Global Kinase Inhibitor in Autoimmune Diseases Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection Market | Substance use disorder Market | Idiopathic Thrombocytopenic Purpura Market | Spinal Fusion Devices Market | Atherectomy Devices Market | Prosthetic Heart Valve Market | Cardiac Monitoring System Market | Chemotherapy-induced nausea and vomiting (CINV) Market | Diabetes Market | Ocular Melanoma Market | Breast Pumps Market | Stereotactic Surgery Devices Market Atopic Dermatitis Market | Concussions Market | Osteoporosis Market | Myelofibrosis (MF) Market | Cancer Cachexia (CC) Market
Related Healthcare Blogs
Evolution in Diabetes Management
Diabetes Management and Care
Increasing Prevalence of Diabetes
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
(Reuters) -Some of the largest U.S. oil producers on Friday signaled productivity and volume gains in the top U.S. shale oil field are slowing, citing disappointing well results and output that is no longer topping their forecasts. U.S. shale oil producer Pioneer Natural Resources on Friday told investors it will reshuffle its drilling portfolio next year to target wells with potentially higher returns, a move to boost lagging productivity levels. Chevron and Exxon Mobil also offered cautious notes on their Permian oil and gas volumes.
Tool maker Stanley Black & Decker was downgraded by a sell- side firm Friday to 'hold' from 'buy' (neutral from outperform). The stock price has been sinking steadily lower for months and the forecast is for more of the same.
Warren Buffett's value-based approach to picking stocks somewhat fell out of favor back in mid-2020, when growth stocks led the market out of its pandemic-prompted pullback. The market environment is more than a little rocky this year, though, and Buffett's philosophy is proving itself once again. Whereas the S&P 500 has been rather deep in the red over the past year of trading, Berkshire Hathaway stock is basically breaking even.
To fight inflationary cost pressure, Coca-Cola (NYSE: KO) raised prices on its portfolio of products. Consumers hardly flinched, continuing to buy its tasty beverages. That demonstration of pricing power reinforces the sustainability of Coca-Cola's dividend long term.
Exxon said it achieved record Permian Basin production and record North American refining throughput during Q3.
Higher commodity price realizations and production, as well as strong refining margins, aid ExxonMobil's (XOM) earnings in Q3.
The bad news is that gasoline prices have spiked on the East Coast. The good news is that prices probably won't climb for long — and the nation, on average, is seeing declines in the fuel's prices at the pump.
Exxon Mobil has gained as oil prices surged and Russia attacked Ukraine, but is XOM still a buy as it announces Q3 earnings?
What economic slowdown? Caterpillar's latest numbers and outlook don't indicate anything even close!
Heart-focused medical device maker Edwards Lifesciences reported a Non-GAAP EPS of $0.61 which missed by $0.01, revenue of $1.32B which missed by $10M. EW has revised their guidance for 2022. A number of fundamental analysts have cut their price targets.
The U.S. market shifted from worries about tight supplies to lower demand for heating fuel on the back of a warmer winter.
Industry executives are touting strong demand and better-than-expected earnings, even as economic speed bumps multiply.
Politan Capital filed a complaint against medical-sensor maker Masimo. Bow Street disclosed a large stake in real estate investment trust Veris Residential.
Facebook parent company Meta Platforms lost more than one-fifth of its market value, or about $76 billion, following the company’s disappointing earnings report. Amazon.com Inc.’s sales forecast for the current quarter missed Wall Street expectations by up to $15 billion. On her first day as permanent chief executive, Sue Gove hosted hundreds of vendors virtually and at the company’s headquarters to lay out a strategy for resuscitating the chain.
The owner of Britain’s largest gas storage site has warned that it is unlikely to be operating at full capacity in time for next winter amid a stand-off with ministers over funding.
U.S. major oil companies had another standout quarter: Combined, Exxon and Chevron reported nearly $31 billion in profits.
In what has been a very impressive earnings season for oil companies, the focus is clearly on rewarding shareholders with dividend hikes and share buybacks
In this article we are going to list the top 10 chemical companies in the world in 2022. Click to skip ahead and jump to the top 5 chemical companies in the world in 2022. The global chemical industry has staged a remarkable comeback after the pandemic occurred, being one of the few industries to […]
ExxonMobil reported $19.7 billion in net income and $112.07 billion in quarterly revenue, while Chevron reported $11.23 billion in profit and $66.64 billion in revenue during the quarter.
Exxon Mobil, Chevron, Shell and BP are part of the Zacks Industry Outlook article.